Source-grounded facts extracted from Inspire Medical Systems, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Inspire Medical Systems, Inc.: Amendment to Certificate of Incorporation to phase out classified board structure and provide for annual election of all directors beginning with 2029 annual meeting, effective May 1, 2026 (effective 2026-05-01).
“On May 1, 2026, the Company filed a Certificate of Amendment to the Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware, which became effective upon filing.”
Inspire Medical Systems, Inc. reported Full Year 2026 results: revenue in the range of $825 million to $875 million, EPS diluted EPS in the range of $0.07 to $0.62 and adjusted diluted EPS in the range of $0.75 to $1.25. Guidance lowered.
“The Company is revising its previously announced revenue outlook to be in the range of $825 million to $875 million, which represents a decline of 4% to 10% compared to 2025. Additionally, the Company now expects annual adjusted operating margin in the range of 2% to 4%, diluted EPS in the range of $0.07 to $0.62 and adjusted diluted EPS in the range of $0.75 to $1.25.”
Inspire Medical Systems, Inc. reported the quarter ended March 31, 2026 results: revenue $204.6 million, net income Net loss was $11.3 million, EPS Diluted EPS was $(0.39) and adjusted diluted EPS was $0.10.
“Revenue increased 1.6% to $204.6 million, primarily driven by increased market penetration, offset by the adverse effects of reimbursement disruption and the Wasteful and Inappropriate Service Reduction (WISeR) program. • Gross margin increased 180 bps to 86.5%, primarily due to increased sales mix of the Inspire V system, which has a higher gross margin than the Inspire IV system. • Operating expenses increased $5.9 million, or 3.4%, to $178.0 million, primarily driven by higher marketing expenses, legal fees and employee-related costs, partially offset by lower R&D expenses. • Operating loss decreased $0.4 million to $1.1 million, and operating margin was (0.5)%. Adjusted operating income was $0.3 million, and adjusted operating margin was 0.2%. • Interest and dividend income decreased by $1.3 million, primarily due to lower average interest rates and lower average cash, cash equivalents, and investment balances. • The effective tax rate was 571.2% compared to 28.1%. The increase in”
Inspire Medical Systems, Inc.: Amended and Restated Bylaws approved by the Board, subject to and effective upon stockholder approval of the Proposed Charter Amendment, removing the provision that directors may be removed only for cause (effective 2026-02-05).
“On February 5, 2026, the Board approved the Amended and Restated Bylaws of the Company (the “Amended Bylaws”), subject to and effective upon the approval of the Proposed Charter Amendment by the stockholders at the Company’s 2026 Annual Meeting.”
Inspire Medical Systems, Inc.: Proposal to declassify the Board of Directors and provide for annual election of directors following a phase-in period, subject to stockholder approval at the 2026 Annual Meeting.
“The Company intends to put forth a proposal at the Company’s annual meeting of stockholders to be held in 2026 (the “2026 Annual Meeting”) to amend its Seventh Amended and Restated Certificate of Incorporation in order to declassify its Board of Directors (the “Board”) and provide for the annual election of directors following a phase-in period (the “Proposed Charter Amendment”).”
Philip J. Ebeling resigned as Chief Operating Officer at Inspire Medical Systems, Inc..
“On July 18, 2024, Philip J. Ebeling notified Inspire Medical Systems, Inc. (the “ Company ”) of his decision to resign as Chief Operating Officer of the Company, effective as of August 9, 2024, in order to pursue a new professional opportunity as President and Chief Executive Officer of a private medical device company operating in the cardiology space.”
Inspire Medical Systems, Inc. shareholders approved Approval, on an Advisory (Non-Binding) Basis, of the Compensation of the Company's Named Executive Officers at the 2024-05-02 meeting.
“Proposal 3 — Approval, on an Advisory (Non-Binding) Basis, of the Compensation of the Company's Named Executive Officers The Company’s stockholders approved, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers by voting as follows:”
Inspire Medical Systems, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2024-05-02 meeting.
“Proposal 2 — Ratification of Appointment of Independent Registered Public Accounting Firm The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2024 by voting as follows:”
Inspire Medical Systems, Inc. shareholders approved Election of Class III directors at the 2024-05-02 meeting.
“Proposal 1 — Election of Directors The following director nominees were elected as Class III directors to hold office until the Company’s annual meeting of stockholders to be held in 2027 and until their respective successors have been duly elected and qualified.”
Inspire Medical Systems, Inc. reported the full year 2024 results: revenue $783 million to $793 million. Guidance raised.
“Inspire is initiating first-time diluted net income per share guidance for the full year 2024 of between $0.10 to $0.20 per share.”
Inspire Medical Systems, Inc. reported the quarter ended March 31, 2024 results: revenue $164.0 million, net income $10.0 million net loss, EPS $0.34 per share net loss per share.
“Revenue was $164.0 million for the three months ended March 31, 2024, a 28% increase from $127.9 million in the corresponding period in the prior year.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.